For the Inventor, By the Inventor

Enter inventor name

San Mateo, CA, United States of America

John R Jacobsen

USPTO Granted Patents = 60 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 5.0

ph-index = 10

Forward Citations = 419(Granted Patents)

Forward Citations (Not Self Cited) = 258(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Francisco, CA (US) (2002 - 2003)
South San Francisco, CA (US) (2022)
San Mateo, CA (US) (2003 - 2023)

Company Filing History:

Theravance, Inc.

Theravance Biopharma R&d Ip, LLC

Theravance Respiratory Company, LLC

Dice Alpha, Inc.

Advanced Medicine, Inc.

Years Active: 2002-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

IL-17A Modulators

JAK Kinase Inhibitors

Respiratory Disease Treatments

Mu Opioid Receptor Antagonists

Muscarinic Receptor Antagonists

Beta2 Adrenergic Receptor Agonists

8-Azabicyclo Compounds

Aminotetralin Derivatives

Disubstituted Alkyl Compounds

Aryl Aniline Compounds

Diamide Compounds

Substituted Benzenecarboxamides

60 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421212 - Substituted benzenecarboxamides as IL-17A modulators (2025-09-23),

2. 12234225 - IL-17 ligands and uses thereof (2025-02-25),

3. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease (2023-08-08),

4. 11548887 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2023-01-10),

5. 11447468 - IL-17 ligands and uses thereof (2022-09-20),

6. 11299492 - JAK kinase inhibitor compounds for treatment of respiratory disease (2022-04-12),

7. 11274094 - Substituted benzenecarboxamides as IL-17A modulators (2022-03-15),

8. 10913740 - JAK kinase inhibitor compounds for treatment of respiratory disease (2021-02-09),

9. 10836744 - Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity (2020-11-17),

10. 10745394 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2020-08-18),

11. 10590107 - Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity (2020-03-17),

12. 10526330 - JAK kinase inhibitor compounds for treatment of respiratory disease (2020-01-07),

13. 10377751 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2019-08-13),

14. 10358433 - Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity (2019-07-23),

15. 10138220 - Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity (2018-11-27),

Title: John R Jacobsen - Pioneering Inventor from San Mateo, CA

Introduction: John R Jacobsen is a renowned inventor based in San Mateo, California, known for his groundbreaking contributions to various industries.

Latest Patents: John R Jacobsen holds several patents in the fields of technology, healthcare, and consumer products, with his most recent inventions focusing on sustainable energy solutions and smart home devices.

Career Highlights: With a career spanning over two decades, John R Jacobsen has worked for leading tech companies, research institutions, and startups, where he has spearheaded innovative projects and brought numerous ideas to life through his inventive spirit.

Collaborations: Throughout his career, John R Jacobsen has collaborated with top engineers, scientists, and designers to create cutting-edge products that have revolutionized the way we live and work. His collaborative efforts have led to the development of award-winning technologies and solutions.

Conclusion: John R Jacobsen's passion for innovation and his relentless pursuit of excellence have established him as a key figure in the world of inventions. His work continues to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…